{'_data': [['Unknown',
            [['GI',
              u'Dyspepsia 13 (4.7) 20 (7.0) Nausea 4 (1.4) 10 (3.5) Abdominal pain 2 (0.7) 6 (2.1) Oesophagitis 2 (0.7) 6 (2.1) General disorders Asthenia 2 (0.7) 4 (1.4) Adverse drug reactions occurring at a frequency < 1%: The following list provides information on adverse drug reactions reported in study MF 4414 and MF 4434 occurring more frequently with ibandronic acid 50 mg film-coated tablets than with placebo: Uncommon: Blood and lymphatic system disorders: anaemia Nervous system disorders: paraesthesia, dysgeusia (taste perversion) Gastrointestinal disorders: haemorrhage, duodenal ulcer, gastritis, dysphagia, abdominal pain, dry mouth Skin and subcutaneous tissue disorders: pruritus Renal and urinary disorders: azotaemia (uraemia) General disorders: chest pain, influenza-like illness, malaise, pain Investigations: blood parathyroid hormone increased Osteonecrosis of the jaw has been reported in patients treated by bisphosphonates. The majority of the reports refer to cancer patients, but such cases have also been reported in patients treated for osteoporosis. Osteonecrosis of the jaw is generally associated with tooth extraction and/or local infection (including osteomyelitis). Diagnosis of cancer, chemotherapy, radiotherapy, corticosteroids and poor oral hygiene are also deemed as risk factors (see section 4.4).']]]],
 '_pages': [5, 6],
 u'_rank': 1,
 u'_type': u'LSFU'}